Prolia (denosumab) / Amgen 
Welcome,         Profile    Billing    Logout  
 110 Diseases   151 Trials   151 Trials   7120 News 


«12345678910111213...8687»
  • ||||||||||  Prolia (denosumab) / Amgen
    Review, Journal:  Osteogenesis imperfecta: shifting paradigms in pathophysiology and care in children. (Pubmed Central) -  Dec 13, 2024   
    This review aims to provide insight into the pathophysiology of OI and the consequences of distinct disease-causing mutations affecting the regulation of bone homeostasis. In this context, we describe the four most recently identified OI-causing genes and provide an update on current approaches for diagnosis and treatment.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Treating Osteoporosis in Patients with Atypical Femoral Fracture. (Pubmed Central) -  Dec 12, 2024   
    Patients who have suffered an atypical femoral fracture while on bisphosphonates or denosumab may continue to be at risk for typical osteoporotic fractures...One potential (but not FDA-approved) method is to use long-term cyclic teriparatide or abaloparatide on a three-months on, three-months off schedule. Tailoring the approach to each patient is important, based on the five clinical principles, in the absence of evidence-based management recommendations.
  • ||||||||||  Prolia (denosumab) / Amgen, Darzalex (daratumumab) / J&J
    Factors Associated with Elevation of Alkaline Phosphatase after First-Line Chemotherapy in Newly Diagnosed Multiple Myeloma By Japan Medical Data Center Claim Database () -  Dec 7, 2024 - Abstract #ASH2024ASH_8950;    
    Logistic analysis revealed that pre-treatment hemoglobin (odds ratio [OR] : 0.849, 95% confidence interval [CI] : 0.754-0.955, per 1g/dL increase; p=0.0066) and corrected Ca concentration (OR : 1.220, 95% CI : 1.030-1.440, per 1mg/dL increase; p =0.0228) were significantly associated with ALP increase. Furthermore, administration of zoledronic acid (OR : 1.580, 95% CI : 1.120-2.220; p=0.0087) and achieving a very good partial response (VGPR) within 6 months (OR : 2.010, 95% CI : 1.180-3.420; p=0.0103) were identified as treatment factors in ALP increase.Conclusion : The study suggests that addressing factors contributing to anemia may be crucial in inducing bone formation in addition to rapid reduction of MM burden and bone resorption.
  • ||||||||||  Columvi (glofitamab-gxbm) / Roche
    Rapid Step-up Dosing Schedule of Glofitamab Is Feasible for Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients () -  Dec 7, 2024 - Abstract #ASH2024ASH_8583;    
    At Day 28 of Cycle 1, efficacy was evaluated using PET-CT or CT scan, and three patients responded to glofitamab (two with partial remission, and one with complete remission), and the other three patients got disease progression.Conclusions : Glofitamab given with a rapid step-up dosing schedule was tolerable in patients with relapsed/refractory DLBCL, and should be used with caution in patients with CNS lymphoma. The efficacy and safety profiles of this rapid step-up schedule needs to be verified in prospective clinical trials.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Giant cell tumor of the cervical spine: A case report. (Pubmed Central) -  Dec 5, 2024   
    Surgeons must have a high level of awareness and perform an adequate preoperative workup, before definitive treatment. The patient should undergo regular follow-ups to detect any recurrence or metastasis at an early stage.
  • ||||||||||  Prolia (denosumab) / Amgen
    Review, Journal:  Pregnancy- and Lactation-Associated Osteoporosis: A Literature Review Based on a Clinical Case. (Pubmed Central) -  Dec 3, 2024   
    Therapies such as bisphosphonates, teriparatide, calcitonin, denosumab, and strontium ranelate have been evaluated, considering their effectiveness and safety...In conclusion, PLO poses a diagnostic challenge due to its low incidence and lack of comprehension of underlying mechanisms. Early diagnosis, personalized treatment, and strict monitoring are crucial for improving the prognosis of these patients.
  • ||||||||||  Prolia (denosumab) / Amgen, Pluvicto (lutetium Lu 177 vipivotide tetraxetan) / Novartis
    Journal:  Repurposing of PSMA-targeted diagnostic and therapeutic agents for the detection and treatment of giant cell tumors of bone. (Pubmed Central) -  Dec 2, 2024   
    Giant cell tumor of bone (GCTB) is a rare bone tumor often necessitating surgical intervention, radiation therapy, or treatment with bisphosphonates or denosumab...PSMA-targeted imaging and radiotherapeutic agents Locametz and Pluvicto are a powerful theranostic pair for detecting and treating PSMA-positive metastatic tumors, including those in bone, and thus have considerable potential to be repurposed for GCTB...Incubation of fresh GCTB tissue samples with FAM-C6-1298 showed increased fluorescence intensity compared to controls, indicating successful targeting of PSMA in GCTB tissue. In conclusion, our data established that PSMA is not only present in the tumor vasculature of GCTB patient tissue but can be effectively targeted with repurposed PSMA-specific radiopharmaceuticals for diagnosis and therapy.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  McCune-Albright Syndrome: A Case From Mauritius. (Pubmed Central) -  Dec 2, 2024   
    In conclusion, our data established that PSMA is not only present in the tumor vasculature of GCTB patient tissue but can be effectively targeted with repurposed PSMA-specific radiopharmaceuticals for diagnosis and therapy. We present a 15-year-old male patient from Mauritius with MAS having multiple caf
  • ||||||||||  Prolia (denosumab) / Amgen
    Review, Journal:  Medical Management for Fracture Prevention in Children with Osteogenesis Imperfecta. (Pubmed Central) -  Nov 29, 2024   
    New therapies are undergoing clinical trials, and it is likely that one or more will receive marketing authorisation within the next three to five years. The long-term outcome from such interventions will need to be studied carefully well beyond the period over which the clinical trials are conducted, and a consistent approach to the collection of data in this regard will be needed as a major collaborative effort.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Denosumab and risk of hypocalcaemia  (Pubmed Central) -  Nov 29, 2024   
    Implementing a 3-month ART interruption before dental extraction is recommended to reduce MRONJ occurrences. No abstract available
  • ||||||||||  Prolia (denosumab) / Amgen
    Review, Journal:  Osteoporosis in Systemic Mastocytosis: A Scoping Review. (Pubmed Central) -  Nov 27, 2024   
    Studies have demonstrated the effectiveness of various treatments depending on the form of mastocytosis, whether indolent systemic or advanced systemic, in the prognosis of the disease. However, this role should be further investigated in additional clinical studies, considering the limited data on the use of these interventions.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Cellular signatures in human blood track bone mineral density in postmenopausal women. (Pubmed Central) -  Nov 22, 2024   
    Our study reveals the distinctive identity of human cOCPs and the potential link between the dynamic regulation of cOCPs and osteoporosis and its treatment. Taken together, our study enhances our understanding of human cOCPs and highlights a potential opportunity to measure cOCPs through a simple blood test, which could potentially identify high-risk individuals.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Denosumab-associated symptomatic hypophosphatemia in normal kidney function: two case reports. (Pubmed Central) -  Nov 20, 2024   
    As prescription rates of denosumab therapy increase, attention should be paid to the risk of developing hypophosphatemia: the risk of such complication may be lower by early and regular monitoring of Ca, Pi, and PTH, as well as early supplementation of phosphate and/or vitamin D as needed. Whenever a patient receiving denosumab therapy complains otherwise unexplained fatigue, exercise intolerance, muscle pain, cramping, and paresthesias, we suggest hypophosphatemia as a potential complication to be ruled out.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  One versus 2 (Pubmed Central) -  Nov 20, 2024   
    P4
    Whenever a patient receiving denosumab therapy complains otherwise unexplained fatigue, exercise intolerance, muscle pain, cramping, and paresthesias, we suggest hypophosphatemia as a potential complication to be ruled out. With the limitations of our small sample size, these data suggest that both 1 and 2
  • ||||||||||  Prolia (denosumab) / Amgen
    Clinical, Journal:  Denosumab for osteoporosis in older adults in long-term care: A randomized trial. (Pubmed Central) -  Nov 16, 2024   
    Treatment with ROMO significantly increased lumbar spine BMD in GC-treated patients, suggesting that ROMO is effective for GIOP. Denosumab was a safe and effective therapy for improving BMD in osteoporotic older men and women with multiple comorbidities in LTC.
  • ||||||||||  Prolia (denosumab) / Amgen
    Enrollment closed, Enrollment change:  FITMI - First In Treating Male Infertility (clinicaltrials.gov) -  Nov 15, 2024   
    P2,  N=180, Active, not recruiting, 
    No abstract available Recruiting --> Active, not recruiting | N=282 --> 180
  • ||||||||||  Prolia (denosumab) / Amgen
    Retrospective data, Journal:  Clinicopathologic and prognostic characteristics of tumor budding-like in giant cell tumor of bone. (Pubmed Central) -  Nov 13, 2024   
    After switching to DEN, ROMO-treated patients continued to gain spine BMD to a greater extent than DEN until Month 24. The current data support the assessment of TBL structures as a reliable prognostic tool in GCTB, potentially aiding in the development of personalized treatment strategies for patients.